Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 18/20 | 0.69 |
| ▸ | BRD4 | O60885 | 15/20 | 0.69 |
| ▸ | BRD7 | Q9NPI1 | 11/20 | 0.69 |
| ▸ | BRD2 | P25440 | 6/20 | 0.69 |
| ▸ | TAF1 | P21675 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.45 |
| ▸ | BPTF | Q12830 | 1/20 | 0.45 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.45 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.45 |
| ▸ | ATAD2B | Q9ULI0 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23575596 | 0.84 | BRD9 (0.49) | BRD9BRD4BRD7BRD2TAF1 | |
| SCHEMBL19869765 | 0.82 | BRD9 (1.00) | BRD9BRD4BRD7BRD2TAF1 | |
| SCHEMBL33531763 | 0.80 | BRD9 (0.67) | BRD9BRD4BRD7BRD2TAF1 | |
| SCHEMBL23575321 | 0.77 | BRD9 (0.45) | BRD9BRD4BRD7BRD2TAF1 | |
| SCHEMBL33532865 | 0.77 | BRD9 (0.72) | BRD9BRD4BRD7BRD2TAF1 | |
| SCHEMBL26353762 | 0.77 | CACNA1G (0.38) | BRD9BRD4BRD7BRD2CD274 | |
| SCHEMBL23783038 | 0.76 | BRD4 (0.53) | BRD9BRD4BRD7BRD2CD274 | |
| SCHEMBL33533083 | 0.75 | BRD9 (0.51) | BRD9BRD4BRD7BRD2TAF1 | |
| SCHEMBL19869768 | 0.75 | BRD9 (0.72) | BRD9BRD4BRD7BRD2TAF1 | |
| SCHEMBL33532986 | 0.74 | BRD4 (0.50) | BRD9BRD4BRD7BRD2TAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | BRD9 3/4885BRD4 161/4885BRD7 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.